Desoxyn Pregnancy Warnings
Animal studies have revealed teratogenic and embryocidal effects when high multiples of the human dose were administered. Data on long-term potential for fertility impairment is not available. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Use is not recommended unless the benefit outweighs the risk.
US FDA pregnancy category: C
Comments: Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight; these infants may experience withdrawal symptoms as demonstrated by dysphoria, including agitation and significant lassitude.
See references
Desoxyn Breastfeeding Warnings
Breastfeeding is not recommending during treatment.
Excreted into human milk: Yes
Comments:
-Breastfeeding should be withheld for 24 to 48 hours if a patient uses methamphetamine while nursing.
-The effect of amphetamine in milk on the neurological development of the breastfed infant has not been well studied.
-Large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established.
-The urinary excretion of amphetamine in a breastfed infant whose mother was taking racemic amphetamine 5 mg four times daily ranged from 0.1% to 0.3% of the mother's urinary excretion; this infant showed no signs of abnormal development during the first 2 years of life.
-The urinary excretion in a breastfed infant whose mother took amphetamine 35 mg daily and exclusively breastfed for 6 months ranged from 1.9% to 2.1% of the mother's urinary excretion; this infant experienced no adverse reactions and grew normally and the mother experienced no adverse effect on milk production.
-In a study of 20 postpartum women, dextroamphetamine reduced serum prolactin by 25% to 32% (7.5 mg IV dose) and 30% to 37% (15 mg IV dose). Another study showed a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40%.
See references
